# OnCo record act-in-sarc (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/act-in-sarc/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "act-in-sarc", "NCT02379845" ;
  schema:name "Act.In.Sarc"@en ;
  schema:alternateName "NBTXR3-301"@en, "ActInSarc"@en ;
  schema:description "Act.In.Sarc showed that injecting hafnium oxide nanoparticles into a soft-tissue sarcoma before preoperative radiotherapy roughly doubled the share of patients whose tumour, once removed, had almost no surviving cancer cells, and that result supported the product's European CE mark in 2019."@en ;
  schema:url <https://onco.cc/trials/act-in-sarc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02379845>, <https://doi.org/10.1016/S1470-2045(19)30326-2>, <https://doi.org/10.1016/j.ijrobp.2022.07.001> ;
  onco:status "positive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/radiosensitisers/> ;
  onco:drugs <https://onco.cc/drugs/nbtxr3/> ;
  onco:companies <https://onco.cc/companies/nanobiotix/> ;
  onco:people <https://onco.cc/people/sylvie-bonvalot/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-act-in-sarc-lancet-oncol-2019/> .